Similar articles

• Optimizing outcomes in rheumatoid arthritis.

  Small RE, Schuna A. Small RE, et al. J Am Pharm Assoc (2003). 2003 Sep-Oct;43(5 Suppl 1):S16-7. doi: 10.1331/154434503322612311. J Am Pharm Assoc (2003). 2003. PMID: 14626516
• [Biologicals in treatment of rheumatoid arthritis and other inflammatory arthropathies].

  Sautner J, Leeb BF. Sautner J, et al. Wien Med Wochenschr. 2003;153(13-14):304-8. doi: 10.1046/j.1563-258x.2003.03036.x. Wien Med Wochenschr. 2003. PMID: 12924105 Review. German.
• [Infections in patients with rheumatoid arthritis receiving anti-cytokine therapy: biological mechanisms and clinical aspects].

  Botsios C, Ostuni P, Sfriso P, Furlan A, Fiocco U, Sgarabotto D, Todesco S. Botsios C, et al. Reumatismo. 2003 Oct-Dec;55(4):224-35. doi: 10.4081/reumatismo.2003.224. Reumatismo. 2003. PMID: 14872221 Review. Italian.
• [Anti-TNF alpha agents in patients with rheumatoid arthritis refractory to conventional therapies].

  González-Gay MA, Agudo M. González-Gay MA, et al. Med Clin (Barc). 2010 May 22;134(15):684-5. doi: 10.1016/j.medcli.2009.12.003. Epub 2010 Feb 21. Med Clin (Barc). 2010. PMID: 20176386 Spanish. No abstract available.
• [Therapeutic efficacy and the adverse effects of newly developed biological agents for rheumatoid arthritis].

  Kondo H. Kondo H. Nihon Naika Gakkai Zasshi. 2004 Jan 10;93(1):153-60. doi: 10.2169/naika.93.153. Nihon Naika Gakkai Zasshi. 2004. PMID: 14968591 Review. Japanese. No abstract available.